Literature DB >> 25620498

Histopathology in the placentae of women with antiphospholipid antibodies: A systematic review of the literature.

Chez A Viall1, Lawrence W Chamley2.   

Abstract

BACKGROUND: Antiphospholipid antibodies (aPLs) are a heterogenous group of autoantibodies associated with recurrent miscarriage, stillbirth, foetal growth restriction and premature birth. The cause of obstetric morbidity in women with aPLs is not completely understood. Workers have attempted to understand the role of aPLs in obstetric morbidity by investigating the histopathology of placentae from aPL-positive women. However, it is unclear from these diverse, and at times contradictory reports what histopathological lesions are common in the placentae of women with aPLs. This systematic review was undertaken to generate a complete picture of the placental features associated with aPLs in an attempt to understand the pathological processes that occur in pregnancies affected by aPLs.
METHODS: Pubmed, Scopus, Web of Science and Embase were searched on the 27th November 2014 using the keywords "placenta" OR "trophoblast" AND "antiphospholipid antibody" OR "antiphospholipid antibody syndrome". Records that were relevant and eligible were qualitatively assessed and given a score out of 24.
RESULTS: Of the 1112 records that were retrieved from the systematic search, 34 records were eligible for review, and were qualitatively scored. Of the 44 histopathological features that were reported in 580 placentae from aPL-positive women, six features appeared to be more common in the placentae of aPL-positive women compared to control women, including: placental infarction, impaired spiral artery remodelling, decidual inflammation, increased syncytial knots, decreased vasculosyncytial membranes and the deposition of complement split product C4d.
CONCLUSION: Based on the evidence in this systematic review, a human placental aPL fingerprint has been proposed. The diversity of the human placental aPL fingerprint suggests that multiple pathological processes may occur in pregnancies affected by aPL.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antiphospholipid antibody; Histopathology; Placenta; Pregnancy; Trophoblast

Mesh:

Substances:

Year:  2015        PMID: 25620498     DOI: 10.1016/j.autrev.2015.01.008

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  34 in total

1.  Pregnancy Outcome in Women with Obstetric and Thrombotic Antiphospholipid Syndrome-A Retrospective Analysis and a Review of Additional Treatment in Pregnancy.

Authors:  Karoline Mayer-Pickel; Katharina Eberhard; Uwe Lang; Mila Cervar-Zivkovic
Journal:  Clin Rev Allergy Immunol       Date:  2017-08       Impact factor: 8.667

Review 2.  Emerging Treatment Models in Rheumatology: Antiphospholipid Syndrome and Pregnancy: Pathogenesis to Translation.

Authors:  Vikki M Abrahams; Lawrence W Chamley; Jane E Salmon
Journal:  Arthritis Rheumatol       Date:  2017-07-18       Impact factor: 10.995

3.  Low molecular weight heparin and aspirin exacerbate human endometrial endothelial cell responses to antiphospholipid antibodies.

Authors:  Zola Chihombori Quao; Mancy Tong; Elena Bryce; Seth Guller; Lawrence W Chamley; Vikki M Abrahams
Journal:  Am J Reprod Immunol       Date:  2017-11-14       Impact factor: 3.886

Review 4.  Vascular Manifestations in Antiphospholipid Syndrome (APS): Is APS a Thrombophilia or a Vasculopathy?

Authors:  Salma Siddique; Jessie Risse; Guillaume Canaud; Stéphane Zuily
Journal:  Curr Rheumatol Rep       Date:  2017-09-04       Impact factor: 4.592

5.  What is the best time to assess the antiphospholipid antibodies (aPL) profile to better predict the obstetric outcome in antiphospholipid syndrome (APS) patients?

Authors:  Jose Omar Latino; Sebastián Udry; Silvia Perés Wingeyer; Diego Fernández Romero; Paula Micone; Gabriela de Larrañaga
Journal:  Immunol Res       Date:  2018-10       Impact factor: 2.829

6.  Complement activation predicts adverse pregnancy outcome in patients with systemic lupus erythematosus and/or antiphospholipid antibodies.

Authors:  Mimi Y Kim; Marta M Guerra; Elianna Kaplowitz; Carl A Laskin; Michelle Petri; D Ware Branch; Michael D Lockshin; Lisa R Sammaritano; Joan T Merrill; T Flint Porter; Allen Sawitzke; Anne M Lynch; Jill P Buyon; Jane E Salmon
Journal:  Ann Rheum Dis       Date:  2018-01-25       Impact factor: 19.103

Review 7.  Lymphocyte Disturbances in Primary Antiphospholipid Syndrome and Application to Venous Thromboembolism Follow-Up.

Authors:  Laurent Simonin; Elisabeth Pasquier; Christophe Leroyer; Divi Cornec; Julie Lemerle; Boutahar Bendaoud; Sophie Hillion; Jacques-Olivier Pers; Francis Couturaud; Yves Renaudineau
Journal:  Clin Rev Allergy Immunol       Date:  2017-08       Impact factor: 8.667

8.  Brief Report: Changes in Antiphospholipid Antibody Titers During Pregnancy: Effects on Pregnancy Outcomes.

Authors:  Cecile M Yelnik; T Flint Porter; D Ware Branch; Carl A Laskin; Joan T Merrill; Marta M Guerra; Michael D Lockshin; Jill P Buyon; Michelle Petri; Lisa R Sammaritano; Mary D Stephenson; Mimi Y Kim; Jane E Salmon
Journal:  Arthritis Rheumatol       Date:  2016-08       Impact factor: 10.995

9.  Antiphospholipid antibody-induced miR-146a-3p drives trophoblast interleukin-8 secretion through activation of Toll-like receptor 8.

Authors:  Stefan M Gysler; Melissa J Mulla; Marta Guerra; Jan J Brosens; Jane E Salmon; Lawrence W Chamley; Vikki M Abrahams
Journal:  Mol Hum Reprod       Date:  2016-03-29       Impact factor: 4.025

Review 10.  Autoimmunity in 2015.

Authors:  Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2016-08       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.